KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Net Income: 2020-2025

Historic Net Income for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to -$162.3 million.

  • Recursion Pharmaceuticals' Net Income fell 69.29% to -$162.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$715.5 million, marking a year-over-year decrease of 89.42%. This contributed to the annual value of -$463.7 million for FY2024, which is 41.33% down from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Net Income stood at -$162.3 million, which was up 5.61% from -$171.9 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Net Income ranged from a high of -$30.5 million in Q1 2021 and a low of -$202.5 million during Q1 2025.
  • Moreover, its 3-year median value for Net Income was -$95.8 million (2024), whereas its average is -$120.8 million.
  • In the last 5 years, Recursion Pharmaceuticals' Net Income tumbled by 153.94% in 2021 and then rose by 6.12% in 2022.
  • Quarterly analysis of 5 years shows Recursion Pharmaceuticals' Net Income stood at -$65.0 million in 2021, then climbed by 6.12% to -$61.0 million in 2022, then slumped by 52.50% to -$93.0 million in 2023, then plummeted by 92.38% to -$178.9 million in 2024, then plummeted by 69.29% to -$162.3 million in 2025.
  • Its last three reported values are -$162.3 million in Q3 2025, -$171.9 million for Q2 2025, and -$202.5 million during Q1 2025.